Effect of BRAFV600E on response to sorafenib in advanced thyroid cancer patients
Volume: 27, Issue: 15_suppl, Pages: 6002 - 6002
Published: May 20, 2009
Abstract
6002 Background: We are conducting an open-label phase II study of sorafenib in patients with metastatic, iodine-refractory thyroid carcinoma. Methods: 55 Patients were administered sorafenib 400 mg orally BID. Responses were monitored by PET and CT. Primary endpoints were response rate (RR) and progression free survival (PFS) by RECIST criteria. BRAF and RAS mutation status is determined by DNA sequencing. Outcome data is evaluated using the...
Paper Details
Title
Effect of BRAFV600E on response to sorafenib in advanced thyroid cancer patients
Published Date
May 20, 2009
Journal
Volume
27
Issue
15_suppl
Pages
6002 - 6002
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History